{'fraction_non_alphanumeric': 0.02345215759849906, 'fraction_numerical': 0.0028142589118198874, 'mean_word_length': 5.58641975308642, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Authors' reply re: Clinical pharmacokinetic properties of magnesium sulphate in women with pre‐eclampsia and eclampsia: a systematic review

western countries, may tilt the balance in the opposite direction. In conclusion, the current pharmacokinetic evidence suggests that, as affirmed by the reviewers, the therapeutic level of magnesium sulphate for seizure control is much lower than was suggested in early studies. Therefore, the low-dose regimen should be widely tried along with pharmacokinetic studies in low-resource countries with lower average maternal weight. Moreover, there could be a qualitative effect of the drug, as the magnesium ion works through more than 300 enzymes in the human body, and the quantity required may be very small. This hypothesis, however, requires rigorous exploration with basic research. Although we highly commend the authors’ effort to enrich us with a succint synthesis of otherwise incomprehensible scattered data addressing an important clinical issue, further information could be gleaned from the existing literature.&